IBM Retirement Fund decreased its holdings in Zoetis Inc (NYSE:ZTS) by 1.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,406 shares of the company’s stock after selling 197 shares during the period. IBM Retirement Fund’s holdings in Zoetis were worth $1,700,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ZTS. Lion Street Advisors LLC purchased a new position in shares of Zoetis in the 1st quarter worth $30,000. Sowa Financial Group Inc. purchased a new position in Zoetis during the fourth quarter valued at $31,000. Danda Trouve Investment Management Inc. purchased a new position in Zoetis during the fourth quarter valued at $32,000. Truvestments Capital LLC purchased a new position in Zoetis during the first quarter valued at $33,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in Zoetis by 99.3% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 289 shares of the company’s stock valued at $34,000 after purchasing an additional 144 shares in the last quarter. 91.45% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on ZTS shares. Barclays lifted their target price on Zoetis from $129.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Argus reissued a “buy” rating on shares of Zoetis in a report on Wednesday, June 3rd. Citigroup decreased their price target on Zoetis from $139.00 to $131.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. UBS Group decreased their price target on Zoetis from $146.00 to $126.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Finally, Jefferies Financial Group assumed coverage on Zoetis in a report on Wednesday, May 27th. They set a “buy” rating and a $152.00 price target on the stock. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Zoetis has an average rating of “Buy” and a consensus price target of $142.36.

Shares of NYSE ZTS traded up $0.44 during trading hours on Wednesday, reaching $138.88. The stock had a trading volume of 36,968 shares, compared to its average volume of 1,604,368. The company has a current ratio of 2.77, a quick ratio of 1.91 and a debt-to-equity ratio of 2.22. The firm has a market cap of $65.72 billion, a price-to-earnings ratio of 41.28, a P/E/G ratio of 4.93 and a beta of 0.77. The business’s fifty day moving average price is $135.99 and its two-hundred day moving average price is $131.55. Zoetis Inc has a 52-week low of $90.14 and a 52-week high of $146.26.

Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, May 6th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.09. The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. Zoetis had a return on equity of 67.72% and a net margin of 25.41%. Zoetis’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.88 earnings per share. Equities research analysts anticipate that Zoetis Inc will post 3.33 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 17th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, July 16th. This represents a $0.80 dividend on an annualized basis and a yield of 0.58%. Zoetis’s dividend payout ratio is currently 21.98%.

In other news, EVP Heidi C. Chen sold 1,179 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $137.29, for a total transaction of $161,864.91. Following the transaction, the executive vice president now directly owns 17,514 shares of the company’s stock, valued at $2,404,497.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 4,463 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $131.02, for a total value of $584,742.26. Following the transaction, the executive vice president now directly owns 40,143 shares in the company, valued at $5,259,535.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,500 shares of company stock valued at $2,439,082. 0.17% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: What is a Backdoor Roth IRA?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.